and meals to induce them to prescribe the MS drugs Avonex (interferon-beta-1a), Tysabri (natalizumab), and Tecfidera (dimethyl fumarate) between 2009 and 2014. That resulted in false claims for ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An investigational monoclonal antibody targeting interferon beta (IFNβ) led to rapid and pronounced reductions in ...

Dazukibart, a type I interferon inhibitor, reduced dermatomyositis disease severity while maintaining a well-tolerated safety ...